tiprankstipranks
Advertisement
Advertisement

WuXi AppTec Sets Final 2025 Dividend and Details Cross-Border Tax Treatment

Story Highlights
  • WuXi AppTec declared a final 2025 cash dividend of RMB 15.7927 per 10 shares, payable in May.
  • The company detailed differing PRC withholding tax rates for various cross-border shareholders in its A and H shares.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
WuXi AppTec Sets Final 2025 Dividend and Details Cross-Border Tax Treatment

Meet Samuel – Your Personal Investing Prophet

WuXi AppTec Co., Ltd. Class H ( (HK:2359) ) just unveiled an announcement.

WuXi AppTec has announced a final cash dividend of RMB 15.7927 per 10 shares for the financial year ended 31 December 2025, following shareholder approval at its 2025 annual general meeting on 28 April 2026. For H-share investors in Hong Kong, the dividend will be paid in Hong Kong dollars at HKD 18.028 per 10 shares, based on an exchange rate of RMB 1 to HKD 1.14154.

The company has set 30 April 2026 as the ex-dividend date, with the record date on 5 May 2026 and payment scheduled for 22 May 2026, and it outlines specific withholding tax rates for different categories of cross-border investors. Non-resident enterprise H-shareholders face a 10% PRC enterprise income tax withholding, investors on the Hong Kong exchange buying A shares are also subject to 10% withholding, while mainland investors in H shares through Shanghai and Shenzhen will have 20% individual income tax withheld, clarifying after-tax returns for various shareholder groups.

The most recent analyst rating on (HK:2359) stock is a Buy with a HK$150.00 price target. To see the full list of analyst forecasts on WuXi AppTec Co., Ltd. Class H stock, see the HK:2359 Stock Forecast page.

More about WuXi AppTec Co., Ltd. Class H

WuXi AppTec Co., Ltd. is a pharmaceutical and life-sciences services company listed in Hong Kong, providing contract research, development and manufacturing services for global healthcare and biopharmaceutical clients. The company operates through both A shares in Shanghai and H shares in Hong Kong, serving domestic Chinese and international investors across these markets.

Average Trading Volume: 4,684,003

Technical Sentiment Signal: Buy

Current Market Cap: HK$339.2B

For detailed information about 2359 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1